Close Menu

NEW YORK (GenomeWeb) – Interpace Diagnostics announced today that it has closed a $3.9 million public offering of its common stock.

The previously announced offering included the sale of 1.2 million shares of Interpace common stock at $3 per share, as well as 108,000 additional shares related to the full exercise of an over-allotment option granted to the underwriters of the transaction.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Mar
18
Sponsored by
Thermo Fisher Scientific

Viruses mutate as they strive to thrive in response to selective pressures.

Mar
29
Sponsored by
Thermo Fisher Scientific

Global genetic surveillance is vital for understanding the evolution of viral pathogens and monitoring for changes in transmissibility, virulence, disease pathology, and impact on the efficacy of diagnostic tests, therapeutics, and vaccines.

Mar
31
Sponsored by
MilliporeSigma

This webinar will outline the development and commercialization journey of a novel CRISPR-based SARS-CoV-2 test.